Saturday, May 19, 2012
INVESTMENT EXTRA: Boost for British biotech firm ImmuPharma
The company's lead drug Lupuzor, for the auto-immune disease lupus, is set to enter phase III clinical trials, meaning the chances of success are greater than 70 per cent.
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment